Get the Stockscreener App
2.15
3.15%
-0.07
After Hours:
2.17
0.02
+0.93%
Alaunos Therapeutics Inc stock is traded at $2.15, with a volume of 16,001.
It is down -3.15% in the last 24 hours and down -12.61% over the past month.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
See More
Previous Close:
$2.22
Open:
$2.21
24h Volume:
16,001
Relative Volume:
0.99
Market Cap:
$5.25M
Revenue:
$3,000
Net Income/Loss:
$-4.11M
P/E Ratio:
-0.9913
EPS:
-2.1688
Net Cash Flow:
$-3.23M
1W Performance:
-2.71%
1M Performance:
-12.61%
6M Performance:
-45.98%
1Y Performance:
-46.20%
1-Day Range:
$2.15
$2.23
1-Week Range:
$2.15
$2.37
52-Week Range:
$1.67
$6.20
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
(346) 355-4099
Address
501 E LAS OLAS BLVD, FORT LAUDERDALE
Compare TCRT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
2.15 | 5.25M | 3,000 | -4.11M | -3.23M | -2.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
Alaunos Therapeutics Inc (TCRT) Institutional Confidence - TradingKey
Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary - Stock Titan
Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TCRT Q4 2023 Earnings: EPS Miss Amid Ongoing Clinical DevelopmentEarnings Surprise Report - newsline.com
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
TCRT Q4 2023 Earnings: EPS Misses Estimates, No Revenue Reported, Stock DeclinesEarnings Stability Report - newsline.com
Alaunos Therapeutics (TCRT) Declines 6.56% as Stock Tests Key Support Near $2.17Swing Trade Setups - newsline.com
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss on Lack of RevenueROE Trend Analysis - newsline.com
Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk - Bez Kabli
Alaunos Therapeutics (TCRT) Declines 4.18% as Biotech Sector Pressure Tests Key Support LevelsQuality ETF - newsline.com
Alaunos Therapeutics Q4 2023 Earnings: EPS Miss Widens as Pre-Revenue Biotech Faces Continued HeadwindsDebt Analysis Report - newsline.com
Alaunos Therapeutics (TCRT) Dips 6.86% as Stock Approaches Critical Support LevelChaikin Flow - The Legal Advocate
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Season Outlook - newsline.com
Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary - Stock Titan
Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers - MSN
Alaunos Therapeutics (TCRT) Drops 2.69% as Support Level Holds SteadyDip Buy Trade - The Legal Advocate
Alaunos Reports Positive Preclinical Metabolic Data for ALN1003 - TipRanks
Alaunos reports preclinical data for obesity drug candidate ALN1003 - Investing.com UK
Alaunos reports preclinical data for obesity drug candidate ALN1003 By Investing.com - Investing.com South Africa
Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers - Quiver Quantitative
ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT) - Stock Titan
TCRT Q4 2023 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueGuidance Update - Newser
Alaunos Therapeutics (TCRT) Q4 2023 Earnings Fall Short: EPS $-4.90 Misses MarkBuyback Announcement Report - Newser
Alaunos Therapeutics Announces Promising Preclinical Results for ALN1003 in Metabolic Syndrome and Obesity Models - Minichart
Alaunos Therapeutics (TCRT) Reveals Promising Preclinical Data f - GuruFocus
Alaunos Therapeutics, Inc.Common Stock (Nasdaq:TCRT) Stock Quote - FinancialContent
Alaunos reports preclinical data for obesity drug candidate - Investing.com UK
Alaunos reports preclinical data for obesity drug candidate By Investing.com - Investing.com Nigeria
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - The Manila Times
Alaunos (Nasdaq: TCRT) shows ALN1003 obesity data, reports $0.354M cash - Stock Titan
Experimental obesity pill shows liver and insulin-resistance effects in mice - Stock Titan
TCRT Alaunos Therapeutics reports widening losses as revenue plummets 50 shares fall 326Social Buy Zones - newser.com
Ziopharm: Q1 Earnings Snapshot - marketscreener.com
Alaunos Therapeutics, Inc. 1Q 2026: Revenue $0K, EPS $(0.59) — 10-Q Summary - TradingView
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Alaunos Therapeutics (NASDAQ: TCRT) Q1 2026 loss, cash runway and Nasdaq equity deficiency - Stock Titan
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):